Pharmaceutical geopolitics is usually mapped through factories. China’s vast pharmaceutical supply chain, India’s strength in low-cost generics and the concentration of patented drug discovery in richer economies have shaped that discussion for years. But that map is becoming incomplete. Two developments in China this past week point to the next layer of competition. Jiangsu province […]
